Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Jennifer Whaley

Nurse Practitioner, Family Beckley, WV Nurse Practitioner

NPI 1174006357 CMS profile 10914629

94 Brookshire Ln, Beckley, WV 25801

Open in the dashboard

General payments

$7,201

350 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jennifer Whaley of Beckley, WV is reported in the CMS Open Payments database as having received $7,201 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,302 65
2023 General $1,891 111
2022 General $2,467 94
2021 General $1,541 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Whaley
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jennifer Whaley were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jennifer Whaley Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,541 $124 $35–$379 $132
2022 $2,467 $141 $44–$430 $149
2023 $1,891 $154 $49–$476 $160
2024 $1,302 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $2,262 94 payments
  2. Janssen Biotech, Inc. $1,035 54 payments
  3. Novartis Pharmaceuticals Corporation $634 42 payments
  4. Sun Pharmaceutical Industries Inc. $563 32 payments
  5. Amgen Inc. $346 11 payments
  6. Pfizer Inc. $336 17 payments
  7. UCB, Inc. $335 27 payments
  8. Regeneron Healthcare Solutions, Inc. $286 9 payments
  9. Dermavant Sciences, Inc. $251 21 payments
  10. Janssen Scientific Affairs, LLC $219 2 payments
  11. Other $935 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $6,830 344 payments
  2. Education $371 6 payments
Products named General payments · program years 2021–2024
  1. SKYRIZI $1,336 48 payments
  2. TREMFYA $1,168 51 payments
  3. RINVOQ $830 38 payments
  4. DUPIXENT $380 10 payments
  5. Otezla $346 11 payments
  6. EUCRISA $336 17 payments
  7. ILUMYA $324 23 payments
  8. CIBINQO $312 16 payments
  9. VTAMA $251 21 payments
  10. COSENTYX $222 11 payments
  11. Other $2,435 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

594

Median for Nurse Practitioner: 389

Drug cost

$427,865

Median for Nurse Practitioner: $21,885

Branded share of claims

8.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 33 $322,120
Otezla Apremilast Brand 19 $93,590
Clindamycin Phosphate Generic 28 $3,640
Ketoconazole Generic 182 $3,437
Triamcinolone Acetonide Generic 65 $1,021
Clobetasol Propionate Generic 33 $963
Ammonium Lactate Generic 43 $925
Tretinoin Generic 19 $778
Mupirocin Generic 51 $368
Hydroxyzine Hcl Generic 46 $342

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$33,444

Medicare's payments for the services billed

Medicare patients

161

Average age 72

Services billed

752

87 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 32%
Depression 32%
Chronic kidney disease 25%
COPD 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $274
$274 — —
RINVOQ
  • AbbVie, Inc. $229
$229 — —
SKYRIZI
  • AbbVie, Inc. $227
$227 — —
Bimzelx
  • UCB, Inc. $151
$151 — —
VTAMA
  • Dermavant Sciences, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record